Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 390

1.

Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation.

Gilbert JR, Zarate CA Jr.

Pharmacol Biochem Behav. 2020 Jan 17:172856. doi: 10.1016/j.pbb.2020.172856. [Epub ahead of print] Review.

PMID:
31958471
2.

Magnetoencephalographic Correlates of Suicidal Ideation in Major Depression.

Gilbert JR, Ballard ED, Galiano CS, Nugent AC, Zarate CA Jr.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2019 Dec 3. pii: S2451-9022(19)30308-8. doi: 10.1016/j.bpsc.2019.11.011. [Epub ahead of print]

PMID:
31928949
3.

Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression.

Acevedo-Diaz EE, Cavanaugh GW, Greenstein D, Kraus C, Kadriu B, Zarate CA, Park LT.

J Affect Disord. 2019 Nov 10. pii: S0165-0327(19)31983-4. doi: 10.1016/j.jad.2019.11.028. [Epub ahead of print]

PMID:
31791675
4.

Neurobiological research with suicidal participants: A framework for investigators.

Ballard ED, Waldman L, Yarrington JS, Gerlus N, Newman LE, Lee L, Sparks M, Liberty V, Pao M, Park L, Zarate CA Jr.

Gen Hosp Psychiatry. 2020 Jan - Feb;62:43-48. doi: 10.1016/j.genhosppsych.2019.11.007. Epub 2019 Nov 19. Review.

PMID:
31775068
5.

Symptom trajectories in the months before and after a suicide attempt in individuals with bipolar disorder: A STEP-BD study.

Ballard ED, Farmer CA, Shovestul B, Vande Voort J, Machado-Vieira R, Park L, Merikangas KR, Zarate CA Jr.

Bipolar Disord. 2019 Nov 18. doi: 10.1111/bdi.12873. [Epub ahead of print]

PMID:
31737973
6.

The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response.

Kadriu B, Farmer CA, Yuan P, Park LT, Deng ZD, Moaddel R, Henter ID, Shovestul B, Ballard ED, Kraus C, Gold PW, Machado-Vieira R, Zarate CA Jr.

Mol Psychiatry. 2019 Nov 15. doi: 10.1038/s41380-019-0589-8. [Epub ahead of print]

PMID:
31732715
7.

Research on the pathophysiology, treatment, and prevention of suicide: practical and ethical issues.

Nugent AC, Ballard ED, Park LT, Zarate CA Jr.

BMC Psychiatry. 2019 Nov 1;19(1):332. doi: 10.1186/s12888-019-2301-6.

8.

Juxtarenal Abdominal Aortic Aneurysm: Results of Open Surgery in an Academic Center.

Drazic OD, Zárate CF, Valdés JF, Krämer AH, Bergoeing MP, Mariné LA, Vargas JF, Mertens RA.

Ann Vasc Surg. 2019 Oct 18. pii: S0890-5096(19)30882-9. doi: 10.1016/j.avsg.2019.10.036. [Epub ahead of print]

PMID:
31634598
9.

The influence of ketamine on drug discovery in depression.

Kraus C, Wasserman D, Henter ID, Acevedo-Diaz E, Kadriu B, Zarate CA Jr.

Drug Discov Today. 2019 Oct;24(10):2033-2043. doi: 10.1016/j.drudis.2019.07.007. Epub 2019 Aug 2. Review.

PMID:
31382015
10.

Multimodal imaging reveals a complex pattern of dysfunction in corticolimbic pathways in major depressive disorder.

Nugent AC, Farmer C, Evans JW, Snider SL, Banerjee D, Zarate CA Jr.

Hum Brain Mapp. 2019 Sep;40(13):3940-3950. doi: 10.1002/hbm.24679. Epub 2019 Jun 9.

PMID:
31179620
11.

Correction to: Mapping anticipatory anhedonia: an fMRI study.

Szczepanik JE, Reed JL, Nugent AC, Ballard ED, Evans JW, Lejuez CW, Zarate CA Jr.

Brain Imaging Behav. 2019 Jun 6. doi: 10.1007/s11682-019-00131-6. [Epub ahead of print]

PMID:
31172359
12.

Depression in the Primary Care Setting. Reply.

Park LT, Zarate CA Jr.

N Engl J Med. 2019 Jun 6;380(23):2279-2280. doi: 10.1056/NEJMc1903259. No abstract available.

13.

What is the optimal serum level for lithium in the maintenance treatment of bipolar disorder? A systematic review and recommendations from the ISBD/IGSLI Task Force on treatment with lithium.

Nolen WA, Licht RW, Young AH, Malhi GS, Tohen M, Vieta E, Kupka RW, Zarate C, Nielsen RE, Baldessarini RJ, Severus E; ISBD/IGSLI Task Force on the treatment with lithium.

Bipolar Disord. 2019 Aug;21(5):394-409. doi: 10.1111/bdi.12805. Epub 2019 Jun 20.

14.

Mapping anticipatory anhedonia: an fMRI study.

Szczepanik JE, Reed JL, Nugent AC, Ballard ED, Evans JW, Lejuez CW, Zarate CA Jr.

Brain Imaging Behav. 2019 Dec;13(6):1624-1634. doi: 10.1007/s11682-019-00084-w. Erratum in: Brain Imaging Behav. 2019 Jun 6;:.

PMID:
31030316
15.

Prognosis and improved outcomes in major depression: a review.

Kraus C, Kadriu B, Lanzenberger R, Zarate CA Jr, Kasper S.

Transl Psychiatry. 2019 Apr 3;9(1):127. doi: 10.1038/s41398-019-0460-3. Review.

16.

Familial Aggregation and Coaggregation of Suicide Attempts and Comorbid Mental Disorders in Adults.

Ballard ED, Cui L, Vandeleur C, Castelao E, Zarate CA Jr, Preisig M, Merikangas KR.

JAMA Psychiatry. 2019 Mar 27. doi: 10.1001/jamapsychiatry.2019.0248. [Epub ahead of print]

PMID:
30916728
17.

(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions.

Zanos P, Highland JN, Stewart BW, Georgiou P, Jenne CE, Lovett J, Morris PJ, Thomas CJ, Moaddel R, Zarate CA Jr, Gould TD.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6441-6450. doi: 10.1073/pnas.1819540116. Epub 2019 Mar 13.

18.

Correction: Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.

Guo W, Machado-Vieira R, Mathew S, Murrough JW, Charney DS, Grunebaum M, Oquendo MA, Kadriu B, Akula N, Henter I, Yuan P, Merikangas K, Drevets W, Furey M, Mann JJ, McMahon FJ, Zarate CA Jr, Shugart YY.

Transl Psychiatry. 2019 Mar 5;9(1):108. doi: 10.1038/s41398-019-0442-5.

19.

Ni(I)-X Complexes Bearing a Bulky α-Diimine Ligand: Synthesis, Structure, and Superior Catalytic Performance in the Hydrogen Isotope Exchange in Pharmaceuticals.

Zarate C, Yang H, Bezdek MJ, Hesk D, Chirik PJ.

J Am Chem Soc. 2019 Mar 27;141(12):5034-5044. doi: 10.1021/jacs.9b00939. Epub 2019 Mar 13.

PMID:
30827090
20.

Effects of Ketamine on Brain Activity During Emotional Processing: Differential Findings in Depressed Versus Healthy Control Participants.

Reed JL, Nugent AC, Furey ML, Szczepanik JE, Evans JW, Zarate CA Jr.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2019 Jul;4(7):610-618. doi: 10.1016/j.bpsc.2019.01.005. Epub 2019 Jan 25.

PMID:
30826253
21.

Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function.

Lumsden EW, Troppoli TA, Myers SJ, Zanos P, Aracava Y, Kehr J, Lovett J, Kim S, Wang FH, Schmidt S, Jenne CE, Yuan P, Morris PJ, Thomas CJ, Zarate CA Jr, Moaddel R, Traynelis SF, Pereira EFR, Thompson SM, Albuquerque EX, Gould TD.

Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5160-5169. doi: 10.1073/pnas.1816071116. Epub 2019 Feb 22.

22.

Functional Imaging of the Implicit Association of the Self With Life and Death.

Ballard ED, Reed JL, Szczepanik J, Evans JW, Yarrington JS, Dickstein DP, Nock MK, Nugent AC, Zarate CA Jr.

Suicide Life Threat Behav. 2019 Dec;49(6):1600-1608. doi: 10.1111/sltb.12543. Epub 2019 Feb 13.

PMID:
30761601
23.

Depression in the Primary Care Setting.

Park LT, Zarate CA Jr.

N Engl J Med. 2019 Feb 7;380(6):559-568. doi: 10.1056/NEJMcp1712493. Review. No abstract available.

24.

Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant.

Wilkinson ST, Farmer C, Ballard ED, Mathew SJ, Grunebaum MF, Murrough JW, Sos P, Wang G, Gueorguieva R, Zarate CA Jr.

Neuropsychopharmacology. 2019 Jun;44(7):1233-1238. doi: 10.1038/s41386-019-0317-8. Epub 2019 Jan 17.

PMID:
30653192
25.

Base-Mediated Defluorosilylation of C(sp2 )-F and C(sp3 )-F Bonds.

Liu XW, Zarate C, Martin R.

Angew Chem Int Ed Engl. 2019 Feb 11;58(7):2064-2068. doi: 10.1002/anie.201813294. Epub 2019 Jan 17.

PMID:
30575235
26.

A Mild and Direct Site-Selective sp2 C-H Silylation of (Poly)Azines.

Gu Y, Shen Y, Zarate C, Martin R.

J Am Chem Soc. 2019 Jan 9;141(1):127-132. doi: 10.1021/jacs.8b12063. Epub 2018 Dec 21.

PMID:
30562018
27.

Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression.

Guo W, Machado-Vieira R, Mathew S, Murrough JW, Charney DS, Grunebaum M, Oquendo MA, Kadriu B, Akula N, Henter I, Yuan P, Merikangas K, Drevets W, Furey M, Mann JJ, McMahon FJ, Zarate CA Jr, Shugart YY.

Transl Psychiatry. 2018 Dec 14;8(1):280. doi: 10.1038/s41398-018-0311-7. Erratum in: Transl Psychiatry. 2019 Mar 5;9(1):108.

28.

Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.

Nugent AC, Wills KE, Gilbert JR, Zarate CA Jr.

Psychiatry Res Neuroimaging. 2019 Jan 30;283:64-66. doi: 10.1016/j.pscychresns.2018.09.001. Epub 2018 Sep 12.

29.

Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ( 2R,6R)-hydroxynorketamine.

Highland JN, Morris PJ, Zanos P, Lovett J, Ghosh S, Wang AQ, Zarate CA Jr, Thomas CJ, Moaddel R, Gould TD.

J Psychopharmacol. 2018 Nov 29:269881118812095. doi: 10.1177/0269881118812095. [Epub ahead of print]

PMID:
30488740
30.

Glutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments.

Kadriu B, Musazzi L, Henter ID, Graves M, Popoli M, Zarate CA Jr.

Int J Neuropsychopharmacol. 2019 Feb 1;22(2):119-135. doi: 10.1093/ijnp/pyy094.

31.

Are 24-hour motor activity patterns associated with continued rapid response to ketamine?

Duncan WC Jr, Slonena EE, Hejazi NS, Brutsche N, Park LT, Henter ID, Ballard ED, Zarate CA Jr.

Neuropsychiatr Dis Treat. 2018 Oct 16;14:2739-2748. doi: 10.2147/NDT.S172089. eCollection 2018.

32.

Disentangling the association of depression on the anti-fatigue effects of ketamine.

Saligan LN, Farmer C, Ballard ED, Kadriu B, Zarate CA Jr.

J Affect Disord. 2019 Feb 1;244:42-45. doi: 10.1016/j.jad.2018.10.089. Epub 2018 Oct 6.

PMID:
30312839
33.

Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.

Gould TD, Zarate CA Jr, Thompson SM.

Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:213-236. doi: 10.1146/annurev-pharmtox-010617-052811. Epub 2018 Oct 8.

34.

Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.

Park L, Furey M, Nugent AC, Farmer C, Ellis J, Szczepanik J, Lener MS, Zarate CA Jr.

Int J Neuropsychopharmacol. 2019 Jan 1;22(1):10-18. doi: 10.1093/ijnp/pyy051.

35.

Evaluation of Recipients of Positive and Negative Secondary Findings Evaluations in a Hybrid CLIA-Research Sequencing Pilot.

Sapp JC, Johnston JJ, Driscoll K, Heidlebaugh AR, Miren Sagardia A, Dogbe DN, Umstead KL, Turbitt E, Alevizos I, Baron J, Bönnemann C, Brooks B, Donkervoort S, Jee YH, Linehan WM, McMahon FJ, Moss J, Mullikin JC, Nielsen D, Pelayo E, Remaley AT, Siegel R, Su H, Zarate C; NISC Comparative Sequencing Program, Manolio TA, Biesecker BB, Biesecker LG.

Am J Hum Genet. 2018 Sep 6;103(3):358-366. doi: 10.1016/j.ajhg.2018.07.018. Epub 2018 Aug 16.

36.

Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects.

Moaddel R, Shardell M, Khadeer M, Lovett J, Kadriu B, Ravichandran S, Morris PJ, Yuan P, Thomas CJ, Gould TD, Ferrucci L, Zarate CA.

Psychopharmacology (Berl). 2018 Oct;235(10):3017-3030. doi: 10.1007/s00213-018-4992-7. Epub 2018 Aug 16.

37.

Ketamine augmentation for major depressive disorder and suicidal ideation: Preliminary experience in an inpatient psychiatry setting.

Sinyor M, Williams M, Belo S, Orser B, Vincent M, Mah L, Zarate C Jr, Castel S, Levitt AJ, Schaffer A.

J Affect Disord. 2018 Dec 1;241:103-109. doi: 10.1016/j.jad.2018.07.073. Epub 2018 Jul 29.

PMID:
30107350
38.

Characterizing the course of suicidal ideation response to ketamine.

Ballard ED, Yarrington JS, Farmer CA, Richards E, Machado-Vieira R, Kadriu B, Niciu MJ, Yuan P, Park L, Zarate CA Jr.

J Affect Disord. 2018 Dec 1;241:86-93. doi: 10.1016/j.jad.2018.07.077. Epub 2018 Jul 30.

39.

Ketamine normalizes brain activity during emotionally valenced attentional processing in depression.

Reed JL, Nugent AC, Furey ML, Szczepanik JE, Evans JW, Zarate CA Jr.

Neuroimage Clin. 2018 Jul 5;20:92-101. doi: 10.1016/j.nicl.2018.07.006. eCollection 2018.

40.

PET radioligand binding to translocator protein (TSPO) is increased in unmedicated depressed subjects.

Richards EM, Zanotti-Fregonara P, Fujita M, Newman L, Farmer C, Ballard ED, Machado-Vieira R, Yuan P, Niciu MJ, Lyoo CH, Henter ID, Salvadore G, Drevets WC, Kolb H, Innis RB, Zarate CA Jr.

EJNMMI Res. 2018 Jul 3;8(1):57. doi: 10.1186/s13550-018-0401-9.

41.

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms.

Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA Jr, Gould TD.

Pharmacol Rev. 2018 Jul;70(3):621-660. doi: 10.1124/pr.117.015198. Review. Erratum in: Pharmacol Rev. 2018 Oct;70(4):879.

42.

7T 1H-MRS in major depressive disorder: a Ketamine Treatment Study.

Evans JW, Lally N, An L, Li N, Nugent AC, Banerjee D, Snider SL, Shen J, Roiser JP, Zarate CA Jr.

Neuropsychopharmacology. 2018 Aug;43(9):1908-1914. doi: 10.1038/s41386-018-0057-1. Epub 2018 Apr 5.

43.

Preventing suicide: A multicausal model requires multimodal research and intervention.

Ballard ED, Zarate CA Jr.

Bipolar Disord. 2018 Sep;20(6):558-559. doi: 10.1111/bdi.12656. Epub 2018 May 5. No abstract available.

44.

Glutamatergic Signaling Drives Ketamine-Mediated Response in Depression: Evidence from Dynamic Causal Modeling.

Gilbert JR, Yarrington JS, Wills KE, Nugent AC, Zarate CA Jr.

Int J Neuropsychopharmacol. 2018 Apr 13. doi: 10.1093/ijnp/pyy041. [Epub ahead of print]

45.

Clinical Trial of the Potassium Channel Activator Diazoxide for Major Depressive Disorder Halted Due to Intolerability.

Kadriu B, Yuan S, Farmer C, Nugent AC, Lener MS, Niciu MJ, Park M, Yazdian A, Ballard ED, Henn FA, Henter ID, Park LT, Zarate CA Jr.

J Clin Psychopharmacol. 2018 Jun;38(3):243-246. doi: 10.1097/JCP.0000000000000866.

46.

Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration.

Evans JW, Szczepanik J, Brutsché N, Park LT, Nugent AC, Zarate CA Jr.

Biol Psychiatry. 2018 Oct 15;84(8):582-590. doi: 10.1016/j.biopsych.2018.01.027. Epub 2018 Feb 15.

47.

Using Neuroimaging to Decipher the Mechanism of Action of Ketamine: A Pathway to Novel Therapeutics?

Nugent AC, Zarate CA Jr.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Oct;2(7):549-551. doi: 10.1016/j.bpsc.2017.08.006. Epub 2017 Oct 5. No abstract available.

48.

Convergent Mechanisms Underlying Rapid Antidepressant Action.

Zanos P, Thompson SM, Duman RS, Zarate CA Jr, Gould TD.

CNS Drugs. 2018 Mar;32(3):197-227. doi: 10.1007/s40263-018-0492-x. Review.

49.

Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression.

Niciu MJ, Shovestul BJ, Jaso BA, Farmer C, Luckenbaugh DA, Brutsche NE, Park LT, Ballard ED, Zarate CA Jr.

J Affect Disord. 2018 May;232:310-315. doi: 10.1016/j.jad.2018.02.049. Epub 2018 Feb 17.

50.

The development of glutamate-based antidepressants is taking longer than expected.

Garay R, Zarate CA Jr, Cavero I, Kim YK, Charpeaud T, Skolnick P.

Drug Discov Today. 2018 Oct;23(10):1689-1692. doi: 10.1016/j.drudis.2018.02.006. Epub 2018 Mar 1. No abstract available.

Supplemental Content

Loading ...
Support Center